Podcasts about interim chief

Three bills were signed into law today to help city agencies crackdown on illegal game rooms. The Honolulu Police Department has a new Interim Chief. A free program at the YMCA teaches kids how to a survive a fall into the water. See omnystudio.com/listener for privacy information.

The Warehouse group is making a profit again, announcing its half-year results for the six months ending 26 January this year. But results did show a revenue drop of 1.6% for the first half of 2024. The Warehouse interim Chief Executive John Journee talks to Ryan Bridge about the results. LISTEN ABOVE.See omnystudio.com/listener for privacy information.

The Warehouse group is making a profit again, announcing its half-year results for the six months ending 26 January this year. But results did show a revenue drop of 1.6% for the first half of 2024. The Warehouse interim Chief Executive John Journee talks to Ryan Bridge about the results. LISTEN ABOVE.See omnystudio.com/listener for privacy information.

Send us a textOver the last 15 years, Steven Antommarchi has held the law enforcement titles of Patrol Officer, Canine Handler, Canine Supervisor, Canine Trainer, and Interim Chief of Police.His first encounter with a K-9 team was in New York City on September 11, 2001. He witnessed a search and rescue K-9 team fighting through horrible conditions, while overcoming serious injury for the sake of saving lives. That encounter made such a profound impression on him that he knew what he wanted to do for the rest of his life.15 years later, on July 7, 2016, in Dallas, Texas, K-9 Officer Antommarchi found himself in the middle of the deadliest attack on law enforcement since 9/11. Tasked with the responsibility of clearing the downtown area for improvised explosive devices, the reason he got into working K-9s came full circle.Being mentored by Tony Guzman and Robert “Bob” Suarez, Antommarchi is the Founder of Next Level K9 Texas, an Instructor for the Texas School Safety Center at Texas State University, and K-9 case study trainer for the Global Forensic Justice Center at Florida International University.Most recently, he became one of the lead trainers and co-designer of the training methodology for a scientific study on “Hemp vs Marijuana.” This study is to evaluate the ability for narcotic detector dogs to discriminate between the odor of marijuana and hemp. The study is being headed by Dr. Kelvin Frank of Florida International University and is in the process of being submitted for publication. Antommarchi is the K-9 trainer and consultant for dozens of law enforcement agencies across the United States and Africa. Conducting workshops and seminars focusing on K-9 aggression instincts, K9 scientific research, and operational readiness. He is also the Law Enforcement Secretary for the American Working DogWe are pleased to announce that Vested Interest in K9's has become our newest sponsor. Vested Interest in K9s, Inc. is a 501c(3) non-profit whose mission is to provide bullet and stab-protective vests and other assistance to dogs. Check it out www.vik9s.org. Please welcome Ray Allen Manufacturing as a sponsor to the podcast. Go to the most trusted name in industry for all of your k9 related equipment. For a 10% discount use the RAMWDDP10 discount code.Welcome our sponsor Gold Coast K9. Gold Coast K9 trains and deploys hand-selected service dogs for personal and family protection, police agencies, and school districts. Their training programs rank among the best and most trusted in the world. Follow Gold Coast k9 on all social media platforms. For 10% off merchandise use the GCK910 discount code on their website www.goldcoastk9.comHLTK9 Conference continues to be a supporter of the WDDP. They are gearing up for the next conference in Myrtle Beach SC. Plan ahead, the 2025 conference will be April 1,2,3, 2025. Register today at www.htlk9.com. Welcome out newest sponsor NCK9LLC. Located in Four Oaks NC, just east of Raleigh NC. Jim O'Brien and staff offer a variety of K9 services. Contact them at Phone : 919-353-7149 Email: jobrien@nck9.us

The interim Chief Medical Officer says artificial intelligence shouldn’t be automatically viewed as a threat, but says we need to be ready to adapt to its growing influence. Professor Mary Horgan, who is from Tralee, was appointed at the interim CMO in June of last year. She addressed the Cantillon 2025 conference in Tralee yesterday

 GUEST: James Lynch on the exit of SPD's Interim Chief //  Chinese chips & TikTok // Carol James, widow of legendary UW coach Don James passes away // SCENARIOS

Comprehensive coverage of the day's news with a focus on war and peace; social, environmental and economic justice. Palestinian displaced persons inspect their tents, which are damaged by wind and rain after heavy rainfall in Deir al-Balah, central Gaza Strip, on November 25, 2024, amid the ongoing war between Israel and Hamas militants. (Photo by Majdi Fathi/NurPhoto via AP) President-elect Trump wants to take over Panama Canal, Canada and Greenland, and re-name the Gulf of Mexico as Gulf of America. A YOUNG PALESTINIAN MOTHER STRUGGLES WITH CANCER AND RAISING HER CHILDREN IN GAZA. W.H.O. ISSUES REPORT ABOUT GROWING INFECTIONS OF H.M.P.V. PATHOGEN. PRESIDENT BIDEN HONORS NATIVE AMERICANS WITH TRIBAL MONUMENTS IN CALIFORNIA. Scandal-plagued Antioch police get new interim chief in wake of racist texting controversy.   The post New national monuments honor California tribes; scandal-plagued Antioch Police pick interim chief – January 7, 2025 appeared first on KPFA.

Fresno Mayor Jerry Dyer and Interim Police Chief Mindy Casto says violent crime in Fresno is down and it's due to the hiring of more police officers. Please Like, Comment and Follow 'Broeske & Musson' on all platforms: --- The ‘Broeske & Musson Podcast’ is available on the KMJNOW app, Apple Podcasts, Spotify or wherever else you listen to podcasts. --- ‘Broeske & Musson' Weekdays 9-11 AM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Facebook | Podcast| X | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

New England native Din Jenkins worked for many years as a police sergeant and educated himself in several administrative functions of a law enforcement agency. He then took that knowledge and skills to the Boston Housing Authority where he rose to lead that specialized agency. Find out more about his journey in this episode.

October 28, 2024 ~ Todd Bettison, Deputy Mayor of Detroit was named interim Chief of Police after James White takes job with The Detroit Wayne Integrated Health Network.

Transporting New Zealand is in favour of boosting diesel reserves. Resource Minister Shane Jones is asking for feedback on increasing the minimum diesel stockholding obligation of 21 days - to 28. Transporting New Zealand interim chief executive, Dom Kalasih, says a strong diesel supply is an important thing to have. He explains more diesel will increase the resilience of our domestic supply chain. LISTEN ABOVESee omnystudio.com/listener for privacy information.

We discuss and debate Erica's in-depth interview with SPD's interim chief Sue Rahr. Plus, Kshama Sawant's campaign against Kamala Harris, and Erica's latest on the city budget. Our editor is Quinn Waller. Thanks to Uncle Ike's pot shop for sponsoring this week's episode! If you want to advertise please contact us at realseattlenice@gmail.comSend us a textThanks to Uncle Ike's pot shop for sponsoring this week's episode! If you want to advertise please contact us at realseattlenice@gmail.comSupport the showYour support on Patreon helps pay for editing, production, live events and the unique, hard-hitting local journalism and commentary you hear weekly on Seattle Nice.

LMPD Interim Chief Paul Humphrey and Sgt. Matt Sanders discussed the arrest of a man who was allegedly assaulting women in various sections of Downtown, the ongoing investigation into the street racing activity across the city, Louisville being a major pathway for drug passage, the new officers on the streets, and how to keep the public engaged in keeping the city safe...

In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.Listen as he discusses:The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV careOptions in people with multiclass resistanceStudies of agents with novel mechanisms of action:BRIGHTE (fostemsavir)TMB-301/-311 (ibalizumab)CAPELLA (lenacapavir) Faculty​​Gregory Huhn, MD, MPHTM,Interim Chief, Division of Infectious DiseasesSenior Director of HIV ServicesCook County HIV Integrated ProgramsInterim Medical Director, The RMR CORE CenterProfessor, Division of Infectious DiseasesRush University Medical CenterChicago, IllinoisFollow along with the slides.https://bit.ly/4fHmxg5Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.    

LMPD's Interim Chief Paul Humphrey discusses the advantage of being from the city and growing-up in the department, changes coming to the handling of sexual harassment claims, the need for more assests and officers, how to slow the violence in our community, and whether or not he wants to be Chief full-time...

Tune in to the latest episode of the Becker's Healthcare Podcast, recorded live at our 14th Annual Meeting, where we delve into insightful discussions with industry experts. Join Ellen Wiegand, SVP & CIO, Interim Chief Data & AI Officer at VCU Health, as they share invaluable insights on leadership, growth strategies, and navigating workforce challenges in healthcare. Gain actionable advice and best practices to elevate your organization's performance in today's dynamic landscape.

Police Positivity - Interim Chief Shawn McCleary - May 13, 2024 by Connect FM

In this episode, we meet with UCHealth Interim Chief Nursing Executive Tamera Dunseth Rosenbaum, DNP, RN, NE-BC, who shares her journey from a bedside nurse to her current role, discussing innovative strategies and opportunities along the way. 

Today on AirTalk, a Texas immigration law has been blocked hours after the Supreme Court allowed the strict immigration law to take effect. Also on the show, LAPD interim Chief Dominic Choi talks with Larry; Why people are turning to smaller community banks; A look into a new course on ‘Culinary Medicine” for patient care; and more. Federal Appeals Court blocks Texas immigration law — again (00:17) Larry interviews LAPD Interim Chief Choi (9:28) Should CA public schools offer Personal Finance Education? (33:26) Why people are making the switch to hometown banks (43:19) A new course examines ‘Culinary Medicine' for patient care (55:33

KFI's Steve Greogry joins Gary and Shannon to talk about Mayor Bass appointing a new LAPD Chief. California is dealing with a shortage of 9-1-1 operators. #TerrorInSkies

In a rare opportunity to look both backwards and into the future of policing in Los Angeles, KNX In Depth talked with outgoing LAPD Chief Michel Moore and incoming Interim Chief Dominic Choi. With Interim Chief Choi taking himself out of the running for consideration as the next LAPD Chief, the city embarks on a comprehensive search effort that will include both internal and external candidates--and, according to Chief Moore, could include a current police chief in a foreign country. From the struggles of reforming LAPD practices over decades to discussing how the Department might receive a fresh face coming in from outside of Los Angeles, KNX gets rarely heard perspectives from the two men tasked with running the third largest police force in the United States.  

In this episode of the Product Thinking podcast, host Melissa Perri is joined by Leah Tharin, Interim Chief Product and Growth Officer, GotPhoto. Join them as they explore the different types of growth strategies and when to use them, as well as the importance of aligning sales and product teams. Leah also talks about the power of data-driven strategies in bridging sales and product teams and how aligning with customer success fuels product-led growth.

Do you live in a state where marijuana is still illegal? If yes, you NEED to listen to this episode. ⁣ ⁣ Disclaimer: They want us to let all of you know that this study will come out after it is peer reviewed the 23rd of February.⁣ ⁣ Episode 207:⁣ Scientifically Speaking, Hemp VS Marijuana⁣ Your Working Dog Radio hosts, Eric @vanessk9 & Ted @ted_summers, sit down with⁣ Steven Antommarchi of @nextlevelk9texas⁣ about a huge K9 study that aimed to see if marijuana trained dogs would hit on hemp (spoiler alert: yes!) The gents also delve a bit into the mitigation piece of the research as well, so don't panic! You'll want to listen to the episode NOW, and then get your paws on the study after it's peer review later this month.⁣ ⁣ ⁣ Over the last 15 years, Antommarchi has held the law enforcement titles of Patrol Officer, Canine Handler, Canine Supervisor, Canine Trainer and Interim Chief of Police.⁣ ⁣ His first encounter with a K9 team was in New York City on September 11, 2001. He witnessed a SAR team fighting through horrible conditions, while overcoming serious injury for the sake of saving lives. That encounter made such a profound impression on him that he knew what he wanted to do for the rest of his life. 15 years later, on July 7, 2016, in Dallas, Texas, K9 Officer Antommarchi found himself in the middle of the deadliest attack on law enforcement since 9/11. Tasked with the responsibility of clearing the downtown area for improvised explosive devices, the reason he got into working K9s came full circle.⁣ ⁣ Being mentored by Tony Guzman and Robert “Bob” Suarez, Antommarchi is the Founder of Next Level K9 Texas, an Instructor for the Texas School Safety Center at Texas State University and K9 case study trainer for the Global Forensic Justice Center at Florida International University.⁣ ⁣ Most recently, he became one of the lead trainers and co-designer of the training methodology for a scientific study on “Hemp vs Marijuana.” This study is to evaluate the ability for narcotic detector dogs to discriminate between the odor of marijuana and hemp. The study is being headed by Dr. Kelvin Frank of Florida International University and is in the process of being submitted for publication.⁣ ⁣ Make sure you give him a follow below.⁣ Personal ⁣ @stevenanto on Facebook ⁣ Work⁣ @nextlevelk9texas on IG and Facebook Join us on our member platform through our youtube channel to get access to perks: https://www.youtube.com/channel/UC8D9WOH6ny8eoiTCxFNpBtQ/join

Take a listen to the latest edition of the Austin Police Association podcast. Interim Chief of Police Robin Henderson sat down with Senior Police Officer Jessica Garner to discuss the current state of APD and how Chief Henderson plans to lead APD into the future. They also highlight the 30x30 initiative and how people can join APD.

Community Connection Tuesday January 16th, 2024 Today on Community Connection, BBB of Indianapolis' Director of Communications, Jennifer Adamany alerts the community to new scam tactics to avoid. Then, Tina is joined by Indianapolis' Interim Chief of Police, Chief Christopher Bailey to discuss his plans for IMPD.See omnystudio.com/listener for privacy information.

The Asheville Police Department hasn't had a homegrown chief in 20 years. Local native Mike Lamb hopes that soon changes. Lamb grew up in Asheville and has been on the force since 1997. In December, city officials named him the interim chief with the sudden retirement of Chief David Zack. This is the second half of my conversation with Interim Chief Lamb. Part One posted January 10. Today, we bore into the often-stated statistic that Asheville Police is down 40 percent of its budgeted officers. We talk about elements of the job Lamb says don't get the attention they should. I ask him about how he and his officers can change a perception many hold, that police come into situations with an adversarial mindset and often use unnecessary force. And Chief Lamb details his own traumatic experience on the job and how he worked through it.Get five news headlines from around Asheville in your morning inbox. No ads, no spam—simple as that. Subscribe for free to the First Look newsletter from The Overlook. Support The Overlook by joining our Patreon campaign!Advertise your event on The Overlook.Instagram: AVLoverlook | Facebook: AVLoverlook | Twitter: AVLoverlookListen and Subscribe: All episodes of The OverlookThe Overlook theme song, "Maker's Song," comes courtesy of the Asheville band The Resonant Rogues.Podcast Asheville © 2023

Your day ahead forecast, Chris Bailey named interim IMPD Chief, Fentanyl death rates leveling out, nearly $2 billion Cummins settlement finalized, and more...See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mike Lamb grew up in Asheville and joined the city's police department in 1998. Over the years, he worked under six different chiefs until last month, when he was named the interim chief with the sudden and surprise retirement of David Zack.Today, I begin a two-part conversation with Interim Chief Mike Lamb. He tells us about his path to law enforcement and what he believes he brings to leadership atop the Asheville Police Department. We also talk about how a carousel of leadership has affected the department, how Chief Lamb views his department's partnership with Buncombe County Sherriffs and the other partnerships he believes is critical to policing a community marked with visible levels of addiction and homelessness.Get five news headlines from around Asheville in your morning inbox. No ads, no spam—simple as that. Subscribe for free to the First Look newsletter from The Overlook. Support The Overlook by joining our Patreon campaign!Advertise your event on The Overlook.Instagram: AVLoverlook | Facebook: AVLoverlook | Twitter: AVLoverlookListen and Subscribe: All episodes of The OverlookThe Overlook theme song, "Maker's Song," comes courtesy of the Asheville band The Resonant Rogues.Podcast Asheville © 2023

Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysplastic syndromes (MDS). In this interview, Dr. Zeidan further delves into his research and what it could mean for the future treatment landscape of MDS.

Battle Ground City Manager Erin Erdman has appointed Michael McCabe to serve in the role of interim police chief following the retirement of former Chief Mike Fort earlier this month. http://tinyurl.com/3ytsukz8 #BattleGround #BattleGroundPoliceDepartment #InterimChiefMichaelMcCabe #ClarkCountySheriffsOffice #SheriffJohnHorch #LawEnforcement #InterlocalAgreement #FormerChiefMikeFort #CityManagerErinErdman #VancouverWa #ClarkCountyWa #ClarkCountyNews #ClarkCountyToday

Recorded live at the 11th Annual Becker's Healthcare CEO + CFO Roundtable, this episode features Niobis Queiro, Interim Chief Revenue Cycle Officer at Nashville General Hospital. Here, she discusses how her organization is approaching payer interactions, the recent increase in denials and slow down in payment times, and more.This episode is brought to you by R1 RCM, a leading provider of technology-driven solutions that transform the financial performance of hospitals, health systems, and medical groups. R1 delivers proven, scalable operating models that power sustainable improvements to net patient revenue, while reducing operating costs. To learn how you can build a future-ready revenue cycle today, visit us at www.r1rcm.com/beckers 

Hospitalisations of young children that could have been prevented with better primary care have dramatically risen. Te Whatu Ora data shows such preventable hospitalisations for children up to four years old jumped 35 percent in the year ending June. That's nationally - and it's even higher for Auckland alone, at 66 percent. Interim chief clinical officer, Dr Richard Sullivan, says more young people are turning up with pneumonia and gastro illnesses. "So we're really focusing on how we support our communities, our primary care colleagues- to really turn that dial around." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Season Two of Small Brains, Big Dreams continues our conversations around mentorship with leading neurologists from around the world. Dr. Lina Chalak has many accomplishments and accolades in her biography, but she's quick to point out the award from UT Southwestern celebrating her work as a mentor holds a special place of honor for her. Listen as she shares her ‘why' and encourages you to do the same.Dr. Lina Chalak (MD, MSCS) is the founding director of both the Neurointensive Care program and the Fetal Neonatal Neurology Fellowship Program at UT Southwestern, where she holds the William Buchanan Chair in Pediatrics and serves as the Interim Chief of Neonatal-perinatal Medicine. She is a Professor in the Departments of Pediatrics and Psychiatry at UT Southwestern Medical Center and an active researcher.Dr. Chalak is board certified in general pediatrics, general pediatrics recertification, neonatal-perinatal medicine, and neonatal-perinatal recertification. She earned her medical degree and completed a residency in pediatrics at American University of Beirut, then fellowships in both neonatal-perinatal medicine and pediatrics at UT Southwestern/Children's Health Dallas. In 2011, she received a Master of Clinical Science Distinction from UT Southwestern's Graduate School of Biomedical Sciences, and in 2021 she earned the school's Best Mentor Award.Dr. Chalak's research focuses on asphyxia, hypothermia, and neonatal brain injury. She led the PRIME mild asphyxia collaborative study and pioneered a Neurovascular bundle for a critical real time evaluation of the coupling of cerebral blood flow and neuronal activity in newborns with asphyxia.For more on Dr. Chalak:https://newbornbrainsociety.org/team-member/lina-f-chalak-md-mscs/Small Brains, Big Dreams is a podcast created by the Newborn Brain Society, in partnership with the Canadian Premature Babies Foundation, and hosted by preemie parent & journalist, Jenna Morton.The Newborn Brain Society is a non-profit organization supporting a world in which all newborns have access to and receive the optimal brain care. We promote international, multi-disciplinary collaboration, education, and innovation among clinicians, scientists, and parents.Connect with us at newbornbrainsociety.org, on Facebook @NewbornBrainSociety, and on Twitter @NewbornBrains.If you've enjoyed this episode, please rate, share & subscribe.

Semaglutide can't fix everything… Recommend lifestyle interventions for weight management with Dr. Will Yancy, Director of the Duke Lifestyle and Weight Management Center and Interim Chief of Division of General Internal Medicine at Duke (@DrWillYancy).  Learn about the ketogenic diet, lower carbohydrate diets, and exercise, and their impacts on your patients.   Claim free CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Credits Producer and writer: Fatima Syed, MD, MSc, FACP Show Notes, Infographic, and Cover Art: Fatima Syed, MD, MSc, FACP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Will Yancy, MD Sponsor: Babbel Get 55% off at Babbel.com/CURB Sponsor: Locumstory  Visit locumstory.com to learn more more about all things locum tenens. Sponsor: Pathway  Download the Pathway app today, 100% free for Curbsiders listeners Full Transcript available HERE

The following question refers to Section 7.3 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. The question is asked by Palisades Medical Center medicine resident & CardioNerds Academy Fellow Dr. Maryam Barkhordarian, answered first by Hopkins Bayview medicine resident & CardioNerds Academy Faculty Dr. Ty Sweeny, and then by expert faculty Dr. Gregg Fonarow. Dr. Fonarow is the Professor of Medicine and Interim Chief of UCLA's Division of Cardiology, Director of the Ahmanson-UCLA Cardiomyopathy Center, and Co-director of UCLA's Preventative Cardiology Program. The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. Question #28 Mr. Gene D'aMeTi, a 53-year-old African American man with ischemic cardiomyopathy and heart failure with reduced ejection fraction (LVEF 30-35%), is recently admitted with acutely decompensated heart failure and acute kidney injury on chronic kidney disease stage III. His outpatient regiment includes sacubitril-valsartan 97-103mg BID, carvedilol 25mg BID, and hydralazine 50mg TID. Sacubitril-valsartan was held because of worsening renal function. Despite symptomatic improvement with diuresis, his renal function continues to decline. He is otherwise well perfused & with preservation of other end organ function.   Throughout this hospitalization, he has steadily become more hypertensive with blood pressures persisting in the 170s/90s mmHg. What would be an appropriate adjustment to his medication regimen at this time? A Resume Losartan only B Start Amlodipine C Increase current Hydralazine dose D Start Isosorbide dinitrate therapy E Both C & D Answer #28 ExplanationThe correct answer is E – both increasing the current hydralazine dose (C) and starting isosorbide dinitrate therapy (D). Although ACEI/ARB therapy (choice A) has shown a mortality and morbidity benefit in HFrEF, caution should be used in patients with renal insufficiency. In this patient with ongoing decline in renal function, RAAS-inhibiting therapies (ACEi, ARB, ARNI, MRA) should be avoided. In this case, as his RAAS-I has been stopped, it would be reasonable to increase current therapies to target doses (or nearest dose tolerated), as these demonstrated both safety and efficacy in trials (Class 1, LOE A). Considering that his high dose ARNI was stopped, it is unlikely that either hydralazine or isosorbide dinitrate alone, even at maximal doses, would be sufficient to control his blood pressure (Options C and D, respectively). Interestingly, in the original study by Massie et. Al (1977), the decision was made to combine these therapies as the result was thought to be superior to either medication alone. ISDN would provide preload reduction, while Hydralazine would decrease afterload. Consequently, we do not have data looking at the individual benefit of either medication in isolation. In self-identified African Americans with NYHA class III or IV HFrEF already on optimal GDMT, the addition of hydralazine & isosorbide dinitrate is recommended to improve symptoms and reduce mortality and morbidity (Class 1, LOE A). In this case, as the patient has evidence of progressive renal disfunction, we are limited in using traditional RAAS-I, such as ACEI, ARB, or ARNI.

This was a joint episode with the guys from the Dogs of War Podcast. The DOW podcast just celebrated its third year. Steven "Sway" Hueston was instrumental in helping us get our podcast off the ground. In this episode we talk about moral, social media, podcast growth, and creative venues for expanding your dog training  business. Additionally, Steven Antommarchi shared some new regarding a study he has been involved in over the past three years. In a nut shell, the study involved the training of dogs to discriminate between hemp and marijuana. Below is Steven's biography:Over the last 15 years, Steven Antommarchi has held the law enforcement titles of Patrol Officer, Canine Handler, Canine Supervisor, Canine Trainer, and Interim Chief of Police.His first encounter with a K-9 team was in New York City on September 11, 2001. He witnessed a search and rescue K-9 team fighting through horrible conditions, while overcoming serious injury for the sake of saving lives. That encounter made such a profound impression on him that he knew what he wanted to do for the rest of his life.15 years later, on July 7, 2016, in Dallas, Texas, K-9 Officer Antommarchi found himself in the middle of the deadliest attack on law enforcement since 9/11. Tasked with the responsibility of clearing the downtown area for improvised explosive devices, the reason he got into working K-9s came full circle.Being mentored by Tony Guzman and Robert “Bob” Suarez, Antommarchi is the Founder of Next Level K9 Texas, an Instructor for the Texas School Safety Center at Texas State University, and K-9 case study trainer for the Global Forensic Justice Center at Florida International University.Most recently, he became one of the lead trainers and co-designer of the training methodology for a scientific study on “Hemp vs Marijuana.” This study is to evaluate the ability for narcotic detector dogs to discriminate between the odor of marijuana and hemp. The study is being headed by Dr. Kelvin Frank of Florida International University and is in the process of being submitted for publication. Antommarchi is the K-9 trainer and consultant for dozens of law enforcement agencies across the United States and Africa. Conducting workshops and seminars focusing on K-9 aggression instincts, K9 scientific research, and operational readiness. He is also the Law Enforcement Secretary for the American Working Dog Association (AWDA) for the disciplines of Narcotics, Patrol, Person Borne IED, Electronic Storage Device detection, Tracking, Trailing, Explosives, Accelerant detection and Personal Protection.We are pleased to have Hold The Line K9 Conference htlk9.com as a sponsor of the The Working Dog Depot Podcast. Joe Lutkowski and his staff are currently securing vendors and presenters for the 2024 conference. The Hold The Line K9 Conference will be in a brand new location. The dates and location are April 9, 10, and 11 in Myrtle Beach South Carolina. There's nothing finer than to be in Carolina in the Spring time. Additional information will be forthcoming. www.htlk9.com We are taking reservations for the Pro Series. If you want Rich and Howard to come to your location we can make it happen. They have come together to provide workshops on any K9 related topic you like. Open to law enforcement and civilian attendees. Contact Howard at hjyk91@gmail.com or 704-473-9885.

The chief joined Mike to discuss topics of the day, recruiting efforts and the DOJ investigation.See omnystudio.com/listener for privacy information.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting, and explain what it means for people with cancer. In today's episode, our guests will discuss new research in breast cancer, lymphoma, multiple myeloma, and brain tumors. First, Dr. Norah Lynn Henry discusses new research in early stage and metastatic breast cancer. Dr. Henry is Professor and Interim Chief of the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and the Breast Oncology Disease Lead at the Rogel Cancer Center. She is also the 2023 Cancer.Net Associate Editor for Breast Cancer. You can view Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi, I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. Welcome to this quick summary of the most exciting new research in breast cancer that was presented at the 2023 ASCO Annual Meeting. I have no conflicts of interest for any of the trials that I will talk about. First, I'm going to give a very brief overview of the types of breast cancer, then talk about some research that was presented on both early-stage and metastatic breast cancer. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive and are stimulated to grow by the hormone estrogen. We treat those cancers with anti-estrogen or anti-endocrine treatments, which block estrogen or lower estrogen levels. Other breast cancers are called HER2-positive. These are often more aggressive cancers. But because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or HER2. These are called triple-negative breast cancer and are also often aggressive cancers. Most of the results I'm going to highlight today are treatments for estrogen receptor-positive and HER2-negative breast cancer. One of the main stories from the ASCO Annual Meeting was the result of the NATALEE trial. At the present time, for patients with estrogen receptor-positive, HER2-negative early-stage breast cancer who were at high risk of having their breast cancer come back, the currently recommended treatment is anti-endocrine therapy. Based on the results of a prior trial called monarchE, we also consider adding a medicine called abemaciclib, which turns off some enzymes in the cell that are called CDK4 and CDK6, which are known to make estrogen receptor-positive breast cancer cells grow. Abemaciclib can further reduce the risk of cancer recurrence compared to endocrine therapy alone, but it does have some side effects, most commonly, diarrhea. In the NATALEE trial, which was presented for the first time at this ASCO meeting, researchers studied a similar type of medication called ribociclib. It acts similarly to abemaciclib, although it is more likely to cause low blood counts and less likely to cause diarrhea. Ribociclib is currently routinely used in combination with anti-endocrine therapy to treat patients with metastatic estrogen receptor-positive breast cancer but is not yet routinely used in the early-stage setting. In the NATALEE trial, patients with estrogen receptor-positive, HER2-negative early-stage breast cancer who are at high risk of breast cancer recurrence were enrolled. Half the patients were treated with just standard anti-endocrine therapy and half also received ribociclib for 3 years. After the 3-year treatment period, those who received both ribociclib and anti-endocrine therapy were about 25% less likely to have their cancer come back compared to those who received only anti-endocrine therapy. Overall, the medication was quite well tolerated. It is important to note that this drug is not yet FDA-approved in the setting. The remaining trials I will highlight are for treatment of metastatic breast cancer. There were many trials examining how best to use drugs that we are actually already using in the clinic. For example, many presentations were about the CDK4/6 inhibitors that I just mentioned. Typically, patients who have just been diagnosed with estrogen receptor-positive, HER2-negative metastatic breast cancer get treated with anti-endocrine therapy plus a CDK4/6 inhibitor. One trial called SONIA examined whether this is the right approach, or whether patients should just get the anti-endocrine therapy up front and hold off on starting the CDK4/6 inhibitor medication until a later time. It appears that this delayed approach would reduce symptoms as well as cost of the medication, while not reducing benefit from the treatment. Therefore, it appears it is likely fine for some patients to get just anti-endocrine therapy alone initially. However, we don't know how to identify those patients. Researchers are still figuring out which patients should follow this new treatment plan and which should keep getting the double therapy at the beginning. Some more to come in the future. There was a different trial called PADA-1 that included patients taking anti-endocrine therapy and the CDK4/6 inhibitor, palbociclib, upfront. Those patients were monitored using a blood test, looking for a mutation or a change in the estrogen receptor in the cancer. Patients who had that mutation either remained on the same treatment that they'd been on or switched to the next line of therapy, even though their scans didn't show any progression of their cancer. Overall, this switching strategy looks like a very promising approach for managing patients since it may help patients' cancer respond to treatment for a longer period of time. Although this approach is not yet officially recommended according to our guidelines. In another example, many patients with all types of metastatic breast cancer are treated with a drug called capecitabine, also known as Xeloda. Although this drug is effective for many cancers, many patients experience hand-foot syndrome, nausea, diarrhea, and mouth sores. In the X7-7 clinical trial, the researchers compared the official standard FDA-approved dose based on a patient's height and weight and given for 14 days followed by 7 days off. That was compared to a fixed dose of treatment given 7 days on and 7 days off. The trial found that the fixed-dose regimen was easier to tolerate, but importantly, the benefit from the 2 doses and schedules of treatment appears to be similar. Therefore, we will likely be using this lower dose, 7 days on and 7 days off, for most of our patients who receive treatment with capecitabine for metastatic breast cancer, since it is likely to improve their quality of life while not negatively impacting the potential benefit they receive from the therapy. There were a lot of other research findings presented that are related to treatment for both early-stage and metastatic breast cancer at the meeting. Importantly, we got glimpses of the many new drugs on the horizon for treatment of breast cancer, including a new antibody-drug conjugate against HER2, as well as other new anti-endocrine and targeted treatments. We eagerly await the results of large, randomized trials so the drugs that work can be used to treat patients with breast cancer. But for now, that's it for this quick summary of important research from the 2023 ASCO Annual Meeting. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. Next, Dr. Christopher Flowers discusses new research in lymphomas and multiple myeloma. Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and Division Head ad interim of Cancer Medicine. He is also the 2023 Cancer.Net Associate Editor for Lymphoma. You can view Dr. Flowers' disclosures at Cancer.Net. Dr. Flowers: Hello. I'm Dr. Christopher Flowers, professor and chair of the Department of Lymphoma and Myeloma and interim division head for cancer medicine at the University of Texas MD Anderson. And it's my pleasure to talk to you today in this Cancer.Net podcast about latest updates in the hematological malignancies focused on lymphoid cancers from the American Society of Clinical Oncology Annual Meeting. The ASCO Annual Meeting every year is an exciting time for latest updates in the care of patients with cancer. And in particular this year, there were 3 abstracts that I'd like to highlight that were presentations at this meeting about lymphoid malignancies that have potential significant impact for patients over time. The first 2 come from a special session that was on late-breaking abstracts that were latest advances from clinical trials. The first is from the ZUMA-7 trial. This is a trial looking at axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, or CAR T-cell therapy. The CAR T-cell trial in question here was led by Jason Westin, who's a colleague of mine at MD Anderson. And MD Anderson is a partner with Kite pharmaceutical company that is a manufacturer of this and has a research alliance with that group. In the ZUMA-7 trial, this was a trial that involved the use of CAR T-cell therapy in comparison to standard-of-care therapy, which typically would be aggressive chemoimmunotherapy followed by autologous stem cell transplantation for patients with relapse of large B-cell lymphoma. As many of you may know, large B-cell lymphoma is a kind of lymphoma that is potentially curable with standard frontline therapy. And when patients relapse, the standard of care historically had been for patients to receive autologous stem cell transplantation, which is also potentially a curative therapy. This trial to do a ZUMA-7 trial compared patients who received the typical standard of care, the autologous stem cell transplant following the aggressive chemoimmunotherapy regimen for patients who had relapsed early after their initial therapy, so within 12 months, or were refractory, meaning that they did not respond to their initial therapy. And this was compared to the axicabtagene ciloleucel or axi-cel CAR T-cell therapy. The initial publication of the trial came out in the New England Journal of Medicine in 2022 and showed that the event-free survival for patients who receive CAR T-cell therapy was superior. This update of the ZUMA-7 trial at the ASCO Annual Meeting that was presented by my colleague, Jason Westin, discussed the overall survival of the study, and in this update, it showed that overall survival was also improved for patients who received axi-cel as opposed to standard-of-care therapy. And now with a median follow-up of a little bit more than 47 months, axi-cel demonstrated superiority that was statistically significant and clinically meaningful over the traditional standard of care. In that same session, there was another trial looking at CAR T-cell therapy for patients with multiple myeloma. This was a BCMA-targeted CAR T-cell therapy that was presented by Dr. Dhakal in that session providing results from the CARTITUDE-4 global randomized phase 3 clinical trial. That was a trial that involved 419 patients where patients were randomized to cilta-cel CAR T-cell therapy for myeloma or standard-of-care therapy, which in this case included combination therapy. And in this trial, this showed that single agent with a single cell-to-cell infusion significantly improved progression-free survival versus standard of care for patients with multiple myeloma who had 1 to 3 prior lines of therapy and were refractory to lenalidomide. This is also a meaningful advance for patients with this disease. And the final abstract that I'll mention is an abstract that was presented by Dr. Alex Herrera from City of Hope and was presented in the Plenary session. And it was really exciting to see a Plenary session presentation focusing on lymphomas. So this trial presented by Dr. Herrera was led by the Southwest Oncology Group. Dr. Sara Ahmed from MD Anderson, from my institution, was a participant and actively engaged in this clinical trial. This trial was a success in a number of ways. First, it involved both pediatric and adult patients and is one of the first trials of its kind to involve both large populations of patients with pediatric lymphomas as well as adults with lymphomas. It helps to consolidate the approaches that we use for Hodgkin lymphoma, both in the pediatric population and the adult population. It also represents a major advance in the ways that we conduct clinical trials in the United States in that this clinical trial finished ahead of schedule in terms of completion of the trial with collaboration from the adult and pediatric groups across the National Clinical Trials Network. As I mentioned, this was presented by Dr. Alex Herrera in the Plenary session and involved patients with stage 3, 4 Hodgkin lymphoma, where patients were randomized 1 to 1 either to receive an anti-PD-1 therapy, nivolumab, with chemotherapy, the AVD chemotherapy regimen, or the antibody-drug conjugate, brentuximab vendotin, combined with that same AVD chemotherapy. And what this showed in 994 patients who were enrolled from 2019 to 2022 was that there was a benefit for patients who received the combination of nivolumab AVD or NAVD versus the group that received brentuximab and AVD. It improved the progression-free survival in patients with advanced-stage Hodgkin lymphoma. In this trial, few immune-related adverse events were observed and a lesser number of patients went on to receive radiation therapy, which is also a benefit for patients with Hodgkin lymphoma. And this concludes my presentation of abstracts at the ASCO Annual Meeting and really exciting advances for patients with lymphoma that were presented this year. ASCO: Thank you, Dr. Flowers. Finally, Dr. Roy Strowd discusses new research in treating brain tumors, including those in people with von Hippel Lindau syndrome. Dr. Strowd is a neurologist and neuro-oncologist at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He is also the 2023 Cancer.Net Associate Editor for Central Nervous System Tumors. You can view Dr. Strowd's disclosures at Cancer.Net. Dr. Strowd: Hello, everyone. This is Roy Strowd. I'm a physician neuro-oncologist at Wake Forest University School of Medicine in our comprehensive cancer center. And I'm really excited to be with you for this podcast on important CNS or brain tumor updates from the 2023 ASCO Annual Meeting. I don't have any relevant disclosures for the research that we'll discuss today. It was a really exciting meeting. It was actually a really fun meeting to be a brain tumor doctor at ASCO this year. So I'm really excited to talk with you about some important updates. And I think it's actually a really important time to be a patient and a caregiver and know some of the things going on in brain tumor care. So I'm going to dive into 3 studies. And one that we just have to talk about, and this was a really exciting study called the INDIGO study. At ASCO, if you present a study, you want to have a Plenary presentation, you want to be up on the big stage presenting your work. And brain tumor studies aren't always on the big stage. We just haven't had enough really good treatments out there for brain tumor patients over the years. And this year, we had a Plenary presentation, a really big study, making a big splash. And that was this INDIGO study. So I'm going to spend a few minutes talking about that study. I want brain tumor patients and caregivers to know about this and know about some of the important updates from the Annual Meeting. The study was called the INDIGO study, and it's a phase 3 study. So when you think about clinical trials, there's a phase 1, phase 2, phase 3. That phase 3 is that last step, that last hurdle that a drug needs to overcome to move towards approval. And a positive phase 3 study is really exciting for the field and means that we may have a new treatment that will change how we take care of brain tumor patients. And that's what this study was. It was also a really unique study. So it's looking at a different group of brain tumor patients, patients that have an IDH mutant glioma. Most common brain tumors that we see are the glioblastomas. And those are often and really, by rule, IDH wild-type. IDH is a gene. It's called the isocitrate dehydrogenase gene. And it's one of these really important genes for us to understand how brain tumors are going to work and how they act and it turns out, with this study, how they may respond to treatment. So this study looked at enrolling patients that had an IDH-mutant low-grade glioma, or a grade 2 glioma. Those are those often slower-growing, but they continuously grow tumors that occur early in life, typically in the 30s or 40s for young people. And we haven't really had a lot of good treatments for these patients. And so this study looked at giving a new drug that's called vorasidenib. It's hard to say vorasidenib. And it's an IDH mutant inhibitor. So it attacks that IDH mutant gene that makes these tumors what they are. And it's been undergoing development for many years. It's an exciting treatment because it's what we call a molecularly targeted treatment. It specifically targets that IDH gene that makes the low-grade tumors low-grade tumors. This study enrolled 331 patients, so a large group of patients. Half of those patients received the drug, the vorasidenib, and half received placebo. And that's pretty uncommon in cancer. We don't often do studies that are placebo-controlled studies. But for these patients, there's often not a good treatment early in the course, they get surgery. And for patients that don't need an additional treatment, we do surgery and then we wait and watch and see what happens. And that gives us an opportunity as a brain tumor community to figure out whether this type of treatment will help prevent the need for a next treatment, prevent the need for radiation and chemotherapy. And so that's what was looked at in this study. And there was some really exciting data. So I'm going to go through a few numbers, but we just got to talk about these numbers because they're really important. So at 14 months, 28% of the patients receiving the drug vorasidenib had progressions. That's about a quarter of patients compared to half that received placebo. So that's a big improvement in the number of patients whose tumor grew. So this drug prevented tumor growth in these patients. And that's exactly what we want. That's why we develop drugs, is to prevent tumor growth. When we look at the time that those patients had until they needed a next treatment or until their tumor grew, it was over 2 years of time patients receiving the drug when their tumor grew versus less than a year, 11 months for those receiving placebo. So it's adding a lot of time for brain tumor patients without tumor growth or without needing another treatment. And typically, these patients with low-grade gliomas would need something like radiation therapy or chemotherapy. And those are good treatments, and we need those treatments. But they can have toxicity. And so this is the type of drug that could prevent that toxicity, cognitive decline, other problems that can happen with chemotherapy that those patients didn't potentially suffer. So there are some important things that we learned from the INDIGO study that I would want you to take away, kind of what do these data mean? The first is that we can target this IDH gene. And that's really important for our field. And it means if you're a brain tumor patient, knowing whether your tumor is IDH mutant or IDH wild-type is important, and that's something I want brain tumor patients to ask me as a neuro-oncologist and ask their cancer doctor because that's important in deciding treatment for them. The second is this medicine vorasidenib, it gets into the brain. And that's one of the big challenges that we have in brain tumor care in developing drugs is we need things that get into the brain. And this study really shows that this is a good medicine. There's a number of IDH inhibitors, but this medicine vorasidenib is one that we want to specifically think about for our patients. And this is a practice-changing study. So for the first time, we now have a treatment that works for grade 2 gliomas and really prevents the need for radiation therapy and chemotherapy. So those are 3 important things to take away from this. There's a number of things that we don't yet know. This medicine is not available. So patients coming in and emailing me and calling me, we don't have it yet. And after a big phase 3 study like this, this is announced. There's still a number of steps that need to happen to make sure that this can be delivered to patients safely and we can get it out there. And that's in partnership with groups like the FDA, the Food and Drug Administration, and others. So this is an important conversation to have with patients, neuro-oncologists, and to know that this is something that's on the horizon. Two other things is we don't know if this is going to work for all brain tumors. In particular, for these IDH wild-type glioblastomas, the most common brain tumor, this probably is not a good therapy that we don't have any data to suggest that it would work. They don't have that IDH mutation. And so this is important for some brain tumor patients but not for everybody. And that needs to prompt a conversation with the cancer doctor. And it may not work at all times. So there's some data to suggest that this is really a drug that's best given early in the course of treatment and not later on. And so it is something that I want my patients to be aware of at the first time that I see them so we can be deciding what kind of the right time is. So I want to give folks 2 take-homes from this study and summarize a few of these things that we heard about because it's such an important study. So what are the 2 take-homes from the INDIGO Study? The first that I wrote down is targeting IDH mutation in glioma works. And that's a groundbreaking discovery from this. This is really important for our field. IDH mutations have been important to diagnose brain tumors but have never been really a therapeutic target. And this changes the landscape, and we can now target IDH mutations in gliomas. And that's really important. The second thing, the second real take-home message, is we can safely delay radiation therapy and chemotherapy in some patients with these lower-grade gliomas, potentially with IDH mutation and IDH inhibition. And that's really important. Chemotherapy and radiation therapy are important, but if we can delay those treatments and prevent side effects, that could be helpful for some of our patients. So really important update from ASCO and what I want to spend most of the time on our podcast focusing on this INDIGO study. But there were a bunch of other things going on in brain tumors at ASCO, as there always are. And I want to highlight 2 studies about some things that the groups of patients may be interested in knowing that happened at the meeting. The first is a study called the INB-200 study. And this is a phase 1 study, so it's earlier in development. But it's an immunotherapy study. And brain tumor patients and caregivers will know that we've really wanted to find an immunotherapy that works for brain tumors. And we haven't yet. And we're still not there, but this study is an important step in that direction. So this study from a group at the University of Alabama looked at something called gamma delta T cells. And T cells are really important. They're part of the anti-tumor response. They're what the body uses to attack the tumor. So we like those T cells. And particularly, these gamma delta T cells are important in targeting tumor cells in glioblastoma cells. They're also unique. They can avoid the toxicity of chemotherapy. Radiation therapy and chemotherapy suppresses the T cells. They make some go down, or decreased in number, which is not what we want. And these gamma delta T cells were genetically created so that they were resistant to chemotherapy. And that's really, really important. We want an immunotherapy that works and one that isn't suppressed by our other treatments. And that's been a real barrier for glioma patients. So in this phase 1 study, they found the right dose of these gamma delta T cells, and that's the goal of a phase 1 study. But there were some early signs that this may be changing the tumor. One of the patients underwent surgery before and after they got this infusion. And we were able to see this. Investigators were able to see the gamma delta T cells up in the tumor. So this doesn't change practice. Patients don't need to go out and seek out the gamma delta T cells yet. But it's one of those early findings that says that we need to keep looking at immunotherapy. And as a community, this is something we need to keep focusing on. And then the last abstract and study I wanted to focus on is for a rare disease. This would not be something that would be relevant for all of our listeners and the brain tumor patients but for a subgroup of patients that have a condition called VHL, or von Hippel-Lindau. And von Hippel-Lindau is a genetic condition. So, most brain tumors are not inherited. You don't get it from a mom or a dad or pass it on, except for these patients, you do. And it comes from a gene that's inherited in families called the VHL or the von Hippel-Lindau gene. And these patients are predisposed to get tumors all throughout the body and the kidneys and the brain and the eye. And this is a lifelong disease where these tumors can really grow slowly over time and cause significant problems. And in the past few years, there's been a new treatment called belzutifan. Belzutifan is the name of this drug that has been shown to be effective in the kidney tumors for patients with VHL. And at ASCO this year, there was a new study showing that it's also effective in treating the brain tumors for these patients. And that's really important. We just haven't had a treatment other than surgery or radiation therapy for these tumors. And oftentimes, they grow after surgery and radiation therapy and we need an additional treatment. So in this study, the investigators looked at, "Does this drug belzutifan work for treating the CNS tumors, hemangioblastoma?" And found that around 50% of patients had a response, so a shrinkage in the size of the tumor. 90% of patients had control of their brain tumor disease, which is really important. And it worked really quickly, so it worked in about 3 to 5 months, which is shorter than what we would see for the kidney tumors. So that's exciting news for VHL patients, patients with von Hippel-Lindau, and another important update from the 2023 ASCO. So thanks for listening to this update of CNS brain tumors at the 2023 ASCO Annual Meeting. Again, I'm Roy Strowd, a neuro-oncologist at Wake Forest University School of Medicine. Delighted to bring you this brief summary of new research in the field. ASCO: Thank you, Dr. Strowd. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Laurel Lyckholm, MD, is a Professor of Hematology/Oncology at the West Virginia University Cancer Institute. She also serves as the Interim Chief of the Department of Hematology/Oncology. She is actively involved with the American Society of Clinical Oncology. Dr. Lyckholm is the recipient of a number of awards, including the Leonard Tow Gold Humanism in Medicine Award and several others for exceptional teaching and mentorship. Every self-improvement, motivational, and leadership literature highlights the inextricable nature of listening with being a high-value professional. “Patients really notice when physicians listen, and you have to listen with your heart as well as your head,” says Dr. Laurel Lyckholm. Join us for another episode of The Medicine Mentors as we discuss implementing listening as a habit in our practice, looking inward when moving past emotional barriers, and using the correct metrics to assess the efficacy of our mentoring relationships with Dr. Laurel Lyckholm. Pearls of Wisdom:   1. Matching is important in mentorship. It's okay to reevaluate mentoring relationships if it's not working out and moving on from them 2. Listening makes the best physician, somebody who is conscious about the listening-to-talking ratio in their meetings with the patients. 3. We should look outward instead of inward. If someone has upset us, maybe they have projected hurt or pain that they are suffering. It's best to move on. 

Dan kicked off the show with an examination and exploration of today's top stories with various experts and reporters. Joining the program was attorney Phil Tracy, WBZ Traffic Reporter Dan Mazella, Debra Poutsiaka, Interim Chief of the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and WBZ Radio Anchor Nichole Davis.

Linda Vahdat, MD, MBA, is a breast cancer medical oncologist. She serves as the Deputy Cancer Center Director, Section Chief of Medical Oncology, and Interim Chief of Hematology at Dartmouth Cancer Center. She is a leading breast cancer researcher with special interests in drug development. She has led three separate drug-development efforts that led to FDA approval of three drugs active in metastatic breast cancer. She founded the Triple Negative Breast Cancer Clinic, the second only in the entire country. Mentorship need not be limited to the confines of medical institutions.“Looking back and thinking about all the people I felt really helped me develop into who I am today, there's actually quite a list because everybody brings something different to the party.” And she ascertains the fact that many of her mentors were outside of medicine. Tune into another insightful conversation on The Medicine Mentors as we discuss building long-term relationships to be conducive to growth and seeking mentors outside of medicine that can supplement our medical practice with Dr. Linda Vahdat. Pearls of Wisdom:   1.  The most successful leaders have high EQs and having a high EQ makes a huge difference. It is a skill that can be learned through different outlets—online courses, specialists, podcasts—where we can begin to understand the underpinnings of EQ. 2. We should ensure that we match properly, either as a mentor or as a mentee, with the other person, and re-evaluate that relationship, that it is not a waste of time for either parties, and communicating if that is so to act as a frequent check of the relationship as well as of goals and objectives that we have set up. 3. A good mentor is someone who listens, creates opportunities, and helps balance life. As mentees, we should follow up and close the loop with our mentors because we have to be respectful of the mentor's time, as well. 4. Mentorship doesn't have to be restricted to just medicine. It is more about learning the approach from individuals not just in medicine but also outside of it. It is important to go out of the box and look for mentors who can help you with a mentorship map.

The following question refers to Section 7.3 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. The question is asked by Palisades Medical Center medicine resident & CardioNerds Intern Dr. Maryam Barkhordarian, answered first by MedStar Washington Hospital Center cardiology hospitalist & CardioNerds Academy Graduate Dr. Luis Calderon, and then by expert faculty Dr. Gregg Fonarow.Dr. Fonarow is the Professor of Medicine and Interim Chief of UCLA's Division of Cardiology, Director of the Ahmanson-UCLA Cardiomyopathy Center, and Co-director of UCLA's Preventative Cardiology Program.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. Question #8 Ms. Flo Zinn is a 60-year-old woman seen in cardiology clinic for follow up of her chronic HFrEF management. She has a history of stable coronary artery disease, hypertension, hypothyroidism, and recurrent urinary tract infections. She does not have a history of diabetes and recent hemoglobin A1c is 5.0%. Her current medications include carvedilol, sacubitril-valsartan, eplerenone, and atorvastatin. Her friend was recently placed on an SGLT2 inhibitor and asks if she should be considered for one as well. Which of the following is the most important consideration when deciding to start this patient on an SGLT2 inhibitor? A The patient does not have a history of type 2 diabetes and so does not qualify for SGLT2 inhibitor therapy B While SGLT2 inhibitors improve hospitalization rates for HFrEF, there is no evidence that they improve cardiovascular mortality C Patients taking SGLT2 inhibitors tend to suffer a more rapid decline in renal function than patients not taking SGLT2 inhibitor therapy D Patients may be at a higher risk for genitourinary infections if an SGLT2 inhibitor is started Answer #8 Explanation   The correct answer is D – SGLT2 inhibitors have been associated with increased risk of genitourinary infections. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors have gathered a lot of press recently as the new kid on the block with respect to heart failure management. While they were initially developed as antihyperglycemic medications for treating diabetes, early cardiovascular outcomes trials showed reduced rates of heart failure hospitalization amongst study participants independent of glucose-lowering effects and irrespective of baseline heart failure status – only 10-14% of patients carried a heart failure diagnosis at baseline. This prompted trials to study the effects of SGLT2 inhibitors in patients with symptomatic chronic HFrEF who were already on guideline directed medical therapy irrespective of the presence of type 2 diabetes mellitus. The DAPA-HF and EMPEROR-Reduced trials showed that dapagliflozin and empagliflozin, respectively, both conferred statistically significant improvements in a composite of heart failure hospitalizations and cardiovascular death (Option B). Most interestingly, these effects were seen irrespective of diabetes history. In light of these findings, the 2022 HF guidelines recommend SGLT2 inhibitors in patients with chronic, symptomatic HFrEF with or without diabetes to reduce hospitalization for HF and cardiovascular mortality (Class I, LOE A). The benefits of SGLT2 inhibitors extend beyond cardiovascular health.

Jamanda Haddock, MA, MRCP, FRCR, Interim Chief of Staff and Chair of Hospital Services at Cleveland Clinic London, joins host Brian Bolwell, MD, to discuss creating teams, setting the emotional tone as a leader, and keeping it fair.

First Aired February 11, 2023Battle Creek City Manager Rebecca Fleury checks in with Community Matters, discussing a variety of areas. Those include her perspective on the interim police chief, a study of the Battle Creek public safety service model and the potential for a citizens review board.Episode ResourcesBattle Creek City Manager Office website(Community Matters 6) Fleury Marks 8 Years as City Manager(Community Matters 11) Mayor Discusses New Commission, Priorities(Community Matters 14) Meet Interim Chief Shannon BagleyMore Community Matters episodesCenter for Public Safety Management (CPSM) websiteABOUT COMMUNITY MATTERSFormer WBCK Morning Show host Richard Piet (2014-2017) returns to host Community Matters, an interview program focused on community leaders and newsmakers in and around Battle Creek. Community Matters is heard Saturdays, 8:00 AM Eastern on WBCK-FM (95.3) and anytime at battlecreekpodcast.com.Community Matters is sponsored by Lakeview Ford Lincoln.Battlecreekpodcast.com and The Richard Piet Show are Livemic Communications podcasts. Livemic Communications helps businesses, organizations and entrepreneurs create customized, purposeful podcast content.

Spasticity is one of the most common symptoms of MS, impacting up to 80% of the people living with MS. It can feel like mild muscle tightness that you wish would just go away or it can be so painful and debilitating that it keeps you from moving. Dr. Michelle Cameron joins me in this episode to discuss what spasticity is and how to best manage it. Dr. Cameron is a neurologist and physical therapist, a professor in the Department of Neurology at Oregon Health & Science University, Interim Chief of Neurology at the VA Portland Healthcare System, and Co-Director of the VA MS Center of Excellence West. We're also talking about a new framework for thinking and talking about MS that's been proposed by an international panel of MS experts. We'll tell you about a study that looked at polypharmacy and MS (Of course, we'll also tell you what polypharmacy is and why you should be aware of it!) We'll share the details around the discovery of human antibodies that have been shown to prevent Epstein-Barr infection (And we'll explain why this could be incredibly important) If you're an MS caregiver, or you know one, I'm asking for just 5 minutes of your time. We're celebrating National Caregivers Month by breaking down the details of the National Family Caregiving Strategy that was recently submitted to Congress. And we're celebrating the indomitable quality of the human spirit by sharing the story of Eric Domingo Roldan and his mom, Sylvia. We have a lot to talk about! Are you ready for RealTalk MS??! Thanksgiving is two days away!  :22 This Week: Managing Spasticity  1:02 Experts propose a new framework for thinking about and talking about MS  2:07 Polypharmacy and MS  5:55 Researchers identify antibodies that prevent Epstein-Barr Virus infection  9:02 If you're an MS caregiver, or you know one, can I have 5 minutes of your time?  11:30 The 2022 National Family Caregivig Strategy   13:55 Eric Domingo Roldan and his mom, Sylvia, make it into the Guinness Book of World Records  16:34 Dr. Michelle Cameron discusses spasticity and MS 18:40 Share this episode  33:55 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/273 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Multiple Sclerosis Progression: Time for a New Mechanism-Driven Frameworkhttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00289-7/fulltext Tremlett's MS Research Explained: Polypharmacy and Multiple Sclerosis: A Population-Based Study https://tremlettsmsresearchexplained.wordpress.com/2022/10/27/polypharmacy-and-multiple-sclerosis-a-population-based-study/ STUDY: Polypharmacy and Multiple Sclerosis: A Population-Based Study https://journals.sagepub.com/doi/full/10.1177/13524585221122207 RealTalk MS Episode 229: Evidence Shows MS Is Triggered by the Epstein-Barr Virus with Dr. Kassandra Munger and Dr. AJ Joshi https://realtalkms.com/229 RealTalk MS Episode 231: Evidence Shows EBV Triggers MS: Understanding the Impact of this Breakthrough Research with Dr. Bruce Bebo https://realtalkms.com/231 STUDY: Epstein-Barr Virus gH/gL Has Multiple Sites of Vulnerability for Virus Neutralization and Fusion Inhibition https://cell.com/immunity/fulltext/S1074-7613(22)00544-1 Take the iConquer MS Caregiver Survey https://realtalkms.com/caregiver 2022 National Strategy to Support Family Caregivers https://acl.gov/sites/default/files/RAISE_SGRG/NatlStrategyToSupportFamilyCaregivers.pdf Eric Domingo Roldan's Instagram Handle @eeRiicbcn Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 273 Guest: Dr. Michelle Cameron Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

This episode features Dr. Gyan Pareek, Interim Chief, Division of Urology, and Co-Director, Minimally Invasive Urology Institute at LifeSpan. Here, he discusses how an aging population is increasing the prevalence of bladder & prostate cancer, the acceleration of robotic surgery, new & innovative drug therapies, and more.

This episode features Dr. Alvia Siddiqi, Interim Chief Medical Officer, Population Health at Advocate Aurora Health. Here, she discusses her work in controlling hypertension and closing the health equity gap in communities of color.

In a special edition of the newscast, Dr. Khalilah LeGrand, the Interim Chief of Staff for the Nebraska Department of Health and Human Services, discusses how the pandemic has impacted public health communications while attending the 2022 National Conference on Health Communication, Marketing and Media, hosted by the National Public Health Information Coalition and the CDC. NPHIC Webpage: 2022 National Conference on Health Communication, Marketing and Media